Clinical Trial Update: Anti-Fibrotic Effects of Losartan In Nash Evaluation Study [Phase 3]

View source ↗

Summary

Phase 3 study evaluating losartan for anti-fibrotic effects in nonalcoholic steatohepatitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Steatohepatitis

Drugs mentioned

• Cozaar (losartan)

Snippet

Sponsor: Newcastle-upon-Tyne Hospitals NHS Trust | Conditions: Nonalcoholic Steatohepatitis | Phase 3 | Status: COMPLETED